Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Core Insights - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA) [3] Group 1: Stock Option Awards - On February 9, 2026, the Compensation Committee of Mineralys granted inducement stock option awards covering 33,504 shares and inducement restricted stock unit awards covering 25,128 shares to two new non-executive employees [1] - The options will vest over a four-year period, with 25% vesting on the first anniversary of the vesting commencement date and 1/48th vesting monthly thereafter, subject to continued service [2] - The restricted stock units will also vest over a four-year period, with 25% vesting on each of the four anniversaries of the vesting commencement date [2] Group 2: Employment Inducement Plan - The awards were granted under Mineralys' 2025 Employment Inducement Incentive Award Plan, which allows for equity awards to new employees [2] - The inducement awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4) [2]